Enterprise Value
37.78M
Cash
8.11M
Avg Qtr Burn
-4.24M
Short % of Float
0.78%
Insider Ownership
2.53%
Institutional Own.
11.19%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MAT2203 (Oral Amphotericin B) Details Cryptococcal meningitis, Meningitis, Azole-resistant infections, Fungal infections, C. krusei infection, Invasive Aspergillosis | Phase 3 Initiation | |
LYPDISO (MAT9001) (Omega-3 Drug) Details Cardiovascular disease | Failed Discontinued |